[New method for intranodular administration of 2,4-dinitro-1-chlorobenzene].
2,4-Dinitro-1-chlorobenzene (DNCB) proved to be an excellent stimulator for immunotherapy of melanom. Because of its poor solubility the therapy is limited to topical application. Our investigations have shown that an aqueous, injectable solution may be obtained by using dimethylsulfoxide (DMSO) that permits solubilization.
D000277:Adjuvants, Pharmaceutic; D004121:Dimethyl Sulfoxide; D004137:Dinitrochlorobenzene / Q000008:administration & dosage*; D007167:Immunotherapy; D007267:Injections; D008545:Melanoma / Q000188:drug therapy; D008722:Methods; D009578:Nitrobenzenes / Q000008:administration & dosage*; D011292:Premedication; D012995:Solubility
D000277:Adjuvants, Pharmaceutic; D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes; D004121:Dimethyl Sulfoxide
Neues Verfahren zur intranodulären Applikation von 2,4-Dinitro-1-chlorbenzol